Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 Jun;95(6):583-5.
doi: 10.1038/clpt.2014.42.

CYP2C9, SLCO1B1, SLCO1B3, and ABCB11 polymorphisms in patients with bosentan-induced liver toxicity

M Roustit  1 , X Fonrose  2 , D Montani  3 , B Girerd  3 , F Stanke-Labesque  4 , N Gonnet  5 , M Humbert  3 , J-L Cracowski  1
Affiliations
Comment

CYP2C9, SLCO1B1, SLCO1B3, and ABCB11 polymorphisms in patients with bosentan-induced liver toxicity

M Roustit et al. Clin Pharmacol Ther. 2014 Jun.

Abstract

Bosentan is an endothelin receptor antagonist used as a first-line treatment in pulmonary arterial hypertension (PAH). Its main adverse effect is a dose-dependent liver toxicity. CYP2C9*2 has recently been shown to be associated with hepatotoxicity in PAH patients. We conducted a nested case-control study to further explore the relationship between functional polymorphisms of gene products involved in bosentan pharmacokinetics (OATP1B1, OATP1B3, and CYP2C9) or hepatobiliary transporters affected by bosentan (ABCB11) and bosentan-induced liver toxicity.

PubMed Disclaimer

Comment on

  • Association of CYP2C9*2 with bosentan-induced liver injury.
    Markova SM, De Marco T, Bendjilali N, Kobashigawa EA, Mefford J, Sodhi J, Le H, Zhang C, Halladay J, Rettie AE, Khojasteh C, McGlothlin D, Wu AH, Hsueh WC, Witte JS, Schwartz JB, Kroetz DL. Markova SM, et al. Clin Pharmacol Ther. 2013 Dec;94(6):678-86. doi: 10.1038/clpt.2013.143. Epub 2013 Jul 17. Clin Pharmacol Ther. 2013. PMID: 23863877 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources